News
Important Only
Theravance Sales Jump 83 Percent
Key PointsRevenue (GAAP) grew 83.2% year over year to $26.2 million in Q2 2025, Revenue (GAAP) exceeded analyst expectations by approximately $0.27 million.Net income (GAAP) reached $54.8 million, driven mainly by a one-time $75.1 million gain from the TRELEGY royalty asset sale.YUPELRI collaboratio...The Motley Fool
Wed, Aug 13
Absci Sales Fall 54 Percent
Key PointsGAAP revenue was $0.6 million for Q2 2025, missing GAAP revenue estimates by 52.3% and Revenue for the three months ended June 30, 2025, was $0.6 million, compared to $1.3 million in the same period of 2024.Research and development spending rose 34% to $20.5 million for the three months en...The Motley Fool
Wed, Aug 13
NeuroPace Revenue Jumps 22 Percent in Q2
Key PointsGAAP revenue rose 22.0% to $23.5 million in Q2 2025, outpacing GAAP estimates by $0.43 million.Gross margin climbed to 77.1%, leading to a raised full-year gross margin outlook of 75% to 76% for FY2025.Operating expenses increased 22.5% year-over-year, primarily driven by one-time personne...The Motley Fool
Wed, Aug 13
Pulse Biosciences Cash Jumps in Q2
Key PointsTotal GAAP costs and expenses, including research and development as well as general and administrative expenses, increased 73.5% year over year for the three months ended June 30, 2025.Cash and cash equivalents climbed to $106.3 million as of Q2 2025, providing a significant runway despit...The Motley Fool
Wed, Aug 13
Nexgel Revenue Jumps 100% in Fiscal Q2
Key PointsGAAP revenue rose 100.3% year over year to $2.88 million in Q2 2025 but missed analyst expectations by 6.5% (GAAP).Gross margin (GAAP) improved significantly to 43.6%, reflecting the impact of branded consumer products and higher utilization.Management maintained full-year 2025 revenue gui...The Motley Fool
Wed, Aug 13
ProKidney Reports 78 Percent Gain in Q2
Key PointsThe Phase 2 REGEN-007 trial for rilparencel demonstrated a 78% reduction in the annual decline of kidney function (eGFR slope), according to topline results reported in July 2025; no serious safety issues reported.The cash runway is projected to extend into mid-2027, aligning with the expe...The Motley Fool
Wed, Aug 13
Zevra Revenue Jumps 486 Percent in Q2
Key PointsGAAP revenue rose to $25.9 million in Q2 2025, exceeding estimates by 14.8%, on strong MIPLYFFA sales and French EAP expansion.GAAP net income reached $74.7 million in Q2 2025, reversing a loss from the prior year, but was fueled by a one-off PRV sale.OLPRUVA performance lagged, prompting ...The Motley Fool
Wed, Aug 13
Fractyl Health Posts 62% Wider Q2 Loss
Key PointsNet loss (GAAP) widened 62% to $27.9 million compared to Q2 2024, as research and development spending rose 26% over the prior year period.No revenue was reported this quarter, in line with expectations.Clinical programs advanced, with full enrollment in pivotal Revita trial cohorts and in...The Motley Fool
Wed, Aug 13
Lineage Cell Revenue Doubles in Q2
Key PointsGAAP revenue doubled in Q2 2025 compared to Q2 2024, significantly beating analyst expectations on a GAAP basis as Collaboration income (GAAP) also doubled compared to Q2 2024.Net loss (GAAP) increased sharply due to large non-recurring impairment and warrant revaluation charges, overshado...The Motley Fool
Wed, Aug 13
Citius Oncology Beats Fiscal Q3 EPS
Key PointsGAAP loss per share of ($0.08) for Q3 FY2025 beat analyst expectations by $0.07No revenue was reported for Q3 FY2025, as LYMPHIR has not yet launched commercially.These 10 stocks could mint the next wave of millionaires › Citius Oncology (NASDAQ:CTOR), a biopharmaceutical company focused o...The Motley Fool
Wed, Aug 13
Kopin Revenue Drops 31% in Fiscal Q2
Key PointsRevenue (GAAP) for Q2 FY2025 missed expectations, coming in 19.6% below analyst estimates, representing a 30.9% decrease from Q2 2024 to $8.5 million (GAAP).Earnings per share (GAAP) were ($0.03) for Q2 FY2025, missing the analyst-predicted GAAP loss of ($0.01) for Q2 2025.Defense sector r...The Motley Fool
Wed, Aug 13
Crypto Shares Jump As Ethereum Breaks $4600; BIT Mining up over 5%; Upexi up Nearly 3%; BitMine up 2%; BTCS, Bit Gigital up 1%
Some crypto shares jumped in overnight trading as Ethereum broke through the $4600 mark at one time.BIT Mining up over 5%; Upexi up nearly 3%; BitMine up 2%; BTCS, Bit Gigital up 1%.Tiger News
Wed, Aug 13
24H | Circle Falls 6%; CoreWeave Stock Sinks over 10%; Luminar Technologies Plunges 17%; CAVA Tumbles 22%
CoreWeave Inc. posted steeper losses as it continued to build to meet demand from artificial intelligence developers and forecast third-quarter operating income that trailed estimates. The company’s shares fell over 10% in overnight trading.Shares of Circle Internet Group Inc. fell 5% in overnight t...Tiger News
Wed, Aug 13
Lululemon Stock Is Down 50% in 2025. Is This a Once-in-a-Lifetime Buying Opportunity Before the Stock Goes Parabolic?
Key PointsLululemon stock has dropped over fears of slowing growth in North America. The brand is doing better than the competition and growing quickly internationally. Management is aggressively repurchasing stock. 10 stocks we like better than Lululemon Athletica Inc. › Lululemon (NASDAQ: LULU) wa...The Motley Fool
Wed, Aug 13
Jefferies flags liquidity risk at Coronado Global Resources
** Jefferies says Australian co Coronado Global Resources' CRN.AX ability to remain going concern depends on successful ramping up of Mammoth and Buchanan mines in December quarter and increasing cash flow at lower unit costs ** Metallurgical coal producer is targeting saleable production of 20....Reuters
Wed, Aug 13
Prediction: Nvidia Stock Will Be Worth This Much by the End of 2025
Key PointsNvidia stock experienced an intense sell-off earlier this year, driven by uncertainty around tariffs and competition in China.Rising infrastructure spending by its largest customers suggests that demand remains strong across the artificial intelligence (AI) landscape.Despite a strong rebou...The Motley Fool
Wed, Aug 13
RPT-COLUMN-High-flying LatAm currencies may struggle to carry on: McGeever
By Jamie McGeeverORLANDO, Florida, Aug 13 (Reuters) - As U.S. President Donald Trump has upended many global economic norms this year, investors have faced several counterintuitive swings, including the dollar's plunge and record highs in bitcoin and U.S. stocks. Now we can add another to that l...Reuters
Wed, Aug 13
From Debt to Deck Chairs: Which Cruise Stock Deserves a Spot in Your Portfolio?
Key PointsRoyal Caribbean is riding high on strong bookings and premium pricing power fueled by its Icon-class ships.Carnival is focused on a financial turnaround while managing operational changes and brand recovery.10 stocks we like better than Royal Caribbean Cruises › After a brutal pandemic-ind...The Motley Fool
Wed, Aug 13
This Artificial Intelligence (AI) Stock Could Be the Nvidia of Quantum Computing
Key PointsNvidia did not become the king of the artificial intelligence (AI) realm overnight; rather, a series of innovations over the last two decades built the foundation for the company's current success. In a similar fashion, Alphabet is building an ecosystem featuring many AI-powered products ...The Motley Fool
Wed, Aug 13
